Flush with $126M raise, Tessa Therapeutics woos new CEO from Takeda

Amber Tong

After some repositioning — and a $126 million financing round to take it down that direction — Singapore’s Tessa Therapeutics has found a new captain to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Flush with $126M raise, Tessa Therapeutics woos new CEO from Takeda

Amber Tong

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

CagriSema’s weight loss data disappointed. What does Novo do next?

WuXi AppTec will sell cell and gene therapy business to private equity firm

Flush with $126M raise, Tes­sa Ther­a­peu­tics woos new CEO from Take­da

Amber Tong

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Flush with $126M raise, Tessa Therapeutics woos new CEO from Takeda

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

CagriSema’s weight loss data disappointed. What does Novo do next?

WuXi AppTec will sell cell and gene therapy business to private equity firm